Alpha psychiatry最新文献

{"title":"Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria.","authors":"Francisco López-Muñoz, Pilar D'Ocón, Alejandro Romero, Domenico De Berardis, Cecilio Álamo","doi":"10.31083/AP40037","DOIUrl":"https://doi.org/10.31083/AP40037","url":null,"abstract":"<p><strong>Objective: </strong>Given their great importance, as one of the most prescribed types of therapeutic drugs worldwide, we have analyzed the role of serendipity in the discovery of new antidepressants, ranging from selective serotonin reuptake inhibitors to more contemporary developments.</p><p><strong>Methods: </strong>We carried out a historical analysis of the discovery of new antidepressants, resorting to the original articles published on their development (initial pharmacological and clinical information) and applied an operational criterion of serendipity developed by our group.</p><p><strong>Results: </strong>Selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, citalopram, paroxetine, sertraline, and escitalopram), selective dopamine and noradrenaline reuptake inhibitors (bupropion), noradrenaline and serotonin reuptake inhibitors (venlafaxine, milnacipram, duloxetine, and desvenlafaxine), selective noradrenaline reuptake inhibitors (reboxetine), noradrenergic and specific serotonergic antidepressants (mirtazapine), melatonergic agonists (agomelatine), and serotonin modulators and stimulators (vortioxetine, vilazodone, tianeptine) correspond to the type IV pattern. Moclobemide, a reversible monoamine oxidase inhibitor, corresponds to the type II pattern, for which the initial serendipitous findings (i.e., the chance discovery of the inhibitory effects of monoamine oxidase (MAO) whilst being studied for their antihyperlipidemic properties) led to subsequent non-serendipitous discoveries (clinical antidepressant efficacy). Ketamine, a glutamatergic modulator, corresponds to the type III pattern, characterized by a non-serendipitous origin (initial development as an anesthetic agent) leading to a serendipitous observation (the discovery of antidepressant efficacy in individuals illicitly using).</p><p><strong>Conclusion: </strong>The majority of new antidepressants adhere to a type IV pattern, characterized by a rational and targeted design process where serendipity played no part, except moclobemide (type II pattern) and ketamine (type III pattern).</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"40037"},"PeriodicalIF":1.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) in Treating Borderline Personality Disorder: A Randomized Controlled Trial.","authors":"Marcelo Nvo-Fernandez, Fabiola Salas, Valentina Miño-Reyes, Francisco Ahumada-Méndez, Pablo Medina, Daniela Avello, Síbila Floriano Landim, Marc Via, Nicholas Napolitano, Marcelo Leiva-Bianchi","doi":"10.31083/AP40031","DOIUrl":"https://doi.org/10.31083/AP40031","url":null,"abstract":"<p><strong>Background: </strong>Eye movement desensitization and reprocessing (EMDR) is recommended by major health organizations for trauma treatment, but its efficacy for borderline personality disorder (BPD) remains unestablished. This study aims to evaluate EMDR's effectiveness in treating BPD through a randomized controlled trial (RCT) and compare its outcomes with cognitive behavioral therapy (CBT).</p><p><strong>Methods: </strong>A total of 76 individuals participated in the RCT, with 18 patients (78% female) completing the study. Participants were randomly assigned to receive either EMDR (n = 8) or CBT (n = 10) via teletherapy sessions. Trauma symptoms were assessed using the international trauma questionnaire (ITQ), BPD symptoms were assessed using the Personality Assessment Inventory-Borderline Features Scale (PAI-BOR), and post-traumatic growth (PTG) was assessed using the post-traumatic growth inventory (PTGI). Additionally, attentional evaluations were conducted at behavioral and electroencephalographic levels through an oddball paradigm. A final comparison was made between a participant who did not complete the therapeutic process and a participant who did.</p><p><strong>Results: </strong>Both EMDR and CBT treatments significantly improved trauma and BPD symptoms, as well as post-traumatic growth. The effect size was moderate for ITQ (η² = 0.615) and PTGI (η² = 0.610), and low for PAI-BOR (η² = 0.147). Symptomatic participants showed a decrease in ITQ (<i>p</i> = 0.006) and PAI-BOR (<i>p</i> = 0.047) scores, and an increase in PTGI scores (<i>p</i> = 0.028).</p><p><strong>Conclusions: </strong>Both EMDR and CBT significantly improved trauma and BPD symptoms, as well as post-traumatic growth. Additionally, EMDR showed benefits in response accuracy and speed, with a correct response rate of 97% when comparing two participants (with and without therapy). However, completely clean electroencephalography (EEG) data were not obtained from both participants for a deeper comparison.</p><p><strong>Clinical trial registration: </strong>The study was registered at https://doi.org/10.1186/ISRCTN91146045, registration number: ISRCTN91146045, registration date: 21 May 2021.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"40031"},"PeriodicalIF":1.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Ziprasidone Injection vs Haloperidol Injection for Agitation in Patients with Acute Schizophrenia.","authors":"Sufang Qi, Wenjie Li, Limin Yang, Guangwei Sun, Xinming Li, Xin Liu, Zhicheng Xue, Yue Zhang, Guanglei Xun","doi":"10.31083/AP40032","DOIUrl":"https://doi.org/10.31083/AP40032","url":null,"abstract":"<p><strong>Objective: </strong>Agitation represents a serious and prevalent symptomatology within acute schizophrenia. This study aims to conduct a nuanced comparison of the efficacy and safety profiles of intramuscular (IM) ziprasidone versus IM haloperidol in the management of agitation among patients with acute schizophrenia.</p><p><strong>Methods: </strong>This investigation was structured as a randomized, 3-day study, utilizing flexible dosing strategies. It included 69 patients diagnosed with schizophrenia, who were randomly allocated to receive either IM ziprasidone (n = 35, 20 to 40 mg/day) or IM haloperidol (n = 34, 5 to 10 mg/day). The primary endpoints included comparative analyses of the change in Positive and Negative Syndrome Scale (PANSS) total scores and Positive and Negative Syndrome Scale Excited Component (PANSS-EC) scores from baseline to study completion across the two groups.</p><p><strong>Results: </strong>At baseline, there were no significant differences between the IM ziprasidone and haloperidol groups. Both treatments led to significant reductions in PANSS-EC total scores (haloperidol, <i>p</i> = 0.001; ziprasidone, <i>p</i> = 0.001) and PANSS total scores (haloperidol, <i>p</i> = 0.001; ziprasidone, <i>p</i> = 0.001) from baseline to study endpoint. Nevertheless, no significant difference was observed between the two groups in terms of changes in PANSS-EC scores (<i>p</i> = 0.312) and PANSS total scores (<i>p</i> = 0.159) from baseline to endpoint. The haloperidol group exhibited a higher incidence of adverse events compared with the ziprasidone group, reaching statistical significance (<i>p</i> = 0.027).</p><p><strong>Conclusions: </strong>Our findings indicate that both medications are equally effective in controlling agitation symptoms. However, ziprasidone exhibited superior characteristics in safety and tolerability, particularly in reducing the incidence of extrapyramidal symptoms.</p><p><strong>Clinical trial registration: </strong>The study was registered at https://www.chictr.org.cn/showproj.html?proj=246996, registration number: ChiCTR2500100002, date of registration: 1 April 2025.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"40032"},"PeriodicalIF":1.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focusing on The Association Between Cavum Septum Pellucidum and/or Cavum Vergae and Clinical Symptoms and Drug Therapy in Patients with Schizophrenia.","authors":"Nermin Gündüz, Ahmet Yosmaoğlu, Erkal Erzincan, Gülçin Şenyuva","doi":"10.31083/AP40036","DOIUrl":"https://doi.org/10.31083/AP40036","url":null,"abstract":"<p><strong>Objective: </strong>Septum pellucidum is a thin midline brain structure located in the anterior brain, running in a median-sagittal or midsagittal direction. This study aims at testing whether cavum septum pellucidum (CSP) and cavum vergae (CV) could predict clozapine pre- scribing in patients with schizophrenia. This study also assesses the relationship between CSP/CV and some clinical findings in patients with schizophrenia.</p><p><strong>Methods: </strong>190 patients diagnosed with schizophrenia who underwent neuroanatomical evaluation with magnetic resonance imaging during inpatient treatment were included in the study. A personal data form, Positive and Negative Syndrome Scale (PANSS) were given to each patient at admission and discharge. The presence or absence of CSP/CV was recorded as \"yes\" or \"no\".</p><p><strong>Results: </strong>The presence of CSP/CV was found to be associated with the number of hospital admissions, the number of electroconvulsive therapy sessions received, PANSS total score at admission, PANSS total score at discharge and clozapine use. In the logistic regression model created, the presence of CSP and total PANSS score were found to predict clozapine prescribing (respectively <i>p</i> = 0.001, <i>p</i> = 0.016). The Nagelkerke's R² value was found to be 0.167.</p><p><strong>Conclusions: </strong>This study holds the distinction of being the first in the field to investigate the relationship between clozapine prescribing and the presence of CSP/CV in schizophrenia patients. There is a need for longitudinal-cohort studies that can better express effect to identify the conditions associated with CSP/CV.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"40036"},"PeriodicalIF":1.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BDNF Gene Polymorphism and Antidepressant Response in Han Chinese Patients with First-Episode Late-Life Depression.","authors":"Han Wu, Jiao-Jiao Zhou, Xue-Yan Chen, Dan-di Zhu, Feng Bao, Wei Zheng, Li Ren, Wei-Gang Pan, Chao-Meng Liu","doi":"10.31083/AP39955","DOIUrl":"https://doi.org/10.31083/AP39955","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the association between brain-derived neurotrophic factor (BDNF) gene polymorphisms and antidepressant response in patients with first-episode late-life depression (LLD).</p><p><strong>Methods: </strong>A total of 72 patients with first-episode LLD were recruited and 57 completed an 8-week course of antidepressant treatment. Participants were assessed at baseline and post-treatment using the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Serum BDNF levels were measured via Enzyme-Linked Immunosorbent Assay (ELISA) and BDNF gene polymorphisms were genotyped using the Agena® MassARRAY system.</p><p><strong>Results: </strong>After 8 weeks, 17 of the 57 patients with LLD showed effective treatment response (effective group), while 40 were classified as ineffective. Significant post-treatment improvements were observed across the cohort in HAMD-17 and RBANS scores, and serum BDNF levels compared with baseline (<i>p</i> < 0.05). However, the effective and ineffective groups did not have significantly different RBANS scores or serum BDNF levels (<i>p</i> > 0.05). Binary logistic regression identified male sex (OR = 10.094, <i>p</i> = 0.007) and BDNF gene polymorphism (OR = 6.559, <i>p</i> = 0.003) as predictors of treatment efficacy.</p><p><strong>Conclusion: </strong>Antidepressant treatment for 8 weeks altered serum BDNF levels in patients with LLD, with male patients carrying the <i>Val/Val</i> genotype potentially responded better to conventional antidepressants. The small sample size may limit the generalizability of these findings.</p><p><strong>Clinical trial registration: </strong>The study was registered at https://www.chictr.org.cn (registration number: ChiCTR1900024445).</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39955"},"PeriodicalIF":1.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.","authors":"Jun Ma, Zhengyuan Huang, Jing Chen, Gaohua Wang","doi":"10.31083/AP39896","DOIUrl":"https://doi.org/10.31083/AP39896","url":null,"abstract":"<p><p>Schizophrenia (SCZ) is a debilitating, chronic mental disorder with an elusive etiology that significantly impacts the life expectancy of affected individuals. Metabolic syndrome (MetS) is a condition characterized by a combination of factors that increase the risk of cardiovascular diseases. MetS is more prevalent in individuals with SCZ and is a major factor that contributes to their reduced lifespan. This review scrutinizes the biological factors that predispose patients with SCZ to MetS, among which, genetic predisposition, dietary and lifestyle modifications, and the use of antipsychotic drugs (APs) play a significant role. The metabolic side effects of APs have been well studied. While studies have shed light on potential interventions to manage MetS in patients with SCZ, identifying precise biological targets to treat SCZ remains challenging. Therefore, further studies are warranted to enhance our comprehension of the intricate mechanisms underlying the susceptibility of patients with SCZ to MetS. These studies will be crucial in developing effective, targeted therapeutic strategies to treat MetS in this vulnerable population.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39896"},"PeriodicalIF":1.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of the COVID-19 Pandemic Lockdown on Self-Harm: A Meta-Analysis.","authors":"Jue Wang, Xueqian Zhang, Hu Deng, Yunlong Tan","doi":"10.31083/AP39868","DOIUrl":"https://doi.org/10.31083/AP39868","url":null,"abstract":"<p><strong>Objective: </strong>The Coronavirus disease 2019 (COVID-19) pandemic caused a range of mental health problems, particularly self-harm. Lockdowns are the usual methods of responding to these public health emergencies. However, the effect of the COVID-19 lockdown on self-harm remains poorly characterized. This study aimed to investigate the influence of the COVID-19 pandemic on the incidence of self-harm. The findings may inform future policy development and strategies for managing pandemic-related mental health challenges.</p><p><strong>Methods: </strong>A meta-analysis was conducted using several database searches: APA PsycINFO, Embase, PubMed, Web of Science, CNKI, and Wan Fang. Published studies with data on the incidence of self-harm during visits to medical institutions, before and during the COVID-19 pandemic, were included. The pooled risk ratio (RR) value of self-harm incidence variation before and during the COVID-19 lockdown period, expressed as the comparison of clinical institution visits before and during the pandemic, was calculated.</p><p><strong>Results: </strong>Fifteen retrospective cohort studies with observational designs involving 253,600 participants were included. The pooled RR value of self-harm incidence variation was 1.386 (95% confidence interval (CI), 1.205-1.595, I² = 58.9%, <i>p</i> = 0.002). The subgroup analysis showed that \"emergency department type\" (<i>p</i> = 0.004) and \"mean age of the sample\" were the sources of the RR values' heterogeneity (<i>p</i> = 0.026).</p><p><strong>Conclusions: </strong>Our findings suggest that the lockdown during the COVID-19 pandemic was a risk factor for self-harm. Therefore, special attention should be paid to individuals visiting the emergency department and the middle-aged and elderly populations.</p><p><strong>The prospero registration: </strong>This study was registered in PROSPERO (CRD42023373026), https://www.crd.york.ac.uk/PROSPERO/view/CRD42023373026.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39868"},"PeriodicalIF":1.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Smartphone-Based Hospital-Family Transitional Care on Symptom Burden and Quality of Life in Elderly Patients with Depression.","authors":"Jianghong Tang, Shilin Zhu, Yuxiang Huang","doi":"10.31083/AP39894","DOIUrl":"https://doi.org/10.31083/AP39894","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effects of smartphone-based hospital-family transitional care on symptom burden and quality of life in elderly patients with depression.</p><p><strong>Methods: </strong>This study retrospective analyzed the clinical data of 168 elderly patients with depression admitted to our hospital from January 2022 to January 2024. A total of 79 patients were included in the reference group (routine transitional management), and 89 subjects were included in the observation group (smartphone-based hospital-family transitional care). The symptom burden and quality of life in both groups before and after management were compared. The main statistical methods used in this study were the chi-squared test and the Mann-Whitney U test.</p><p><strong>Results: </strong>Before discharge, no significant difference existed in Geriatric Depression Scale (GDS) scores, P300 latency, P300 amplitude, Montreal Cognitive Assessment (MoCA) scores, and the scores of each domain in the World Health Organization Quality of Life (WHOQOL)-BREF between the two groups (all <i>p</i> > 0.05). After 5 months, the observation group demonstrated a significantly lower GDS score (<i>p</i> = 0.016), shorter P300 latency (<i>p</i> < 0.001), higher P300 amplitude (<i>p</i> < 0.001), higher MoCA score (<i>p</i> = 0.001), and significantly higher scores in physiological, psychological, and environmental domains than the reference group (<i>p</i> < 0.001), with no significant difference in social relation domain (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>Smartphone-based hospital-family transitional care can improve the symptom burden, cognitive function, and quality of life of elderly patients with depression.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39894"},"PeriodicalIF":1.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Evaluation of the Montreal Cognitive Assessment Basic Scale Against the Mini-Mental State Examination for Post-Stroke Cognitive Impairment.","authors":"Qingjun Zhu, Meirong Chen, Xiang Li, Lin Huang, Jinling Qiao, Miaocun Chen, Huizhi Ma","doi":"10.31083/AP39895","DOIUrl":"https://doi.org/10.31083/AP39895","url":null,"abstract":"<p><strong>Background: </strong>The Montreal Cognitive Assessment Basic scale (MoCA-B) is more sensitive than the Mini-Mental State Examination (MMSE) for detecting mild cognitive impairment due to Alzheimer's disease (AD). To explore the diagnostic efficacy of the Chinese version of the MoCA-B against the MMSE for post-stroke cognitive impairment (PSCI).</p><p><strong>Methods: </strong>Eighty four patients with acute cerebral infarction were grouped into a post-stroke cognitive normal (PSCN) or a PSCI group based on their scores on the Clinical Dementia Rating scale (CDR), the gold standard for diagnosing PSCI. They were evaluated by using the MMSE and MoCA-B scales, then the area under the receiver operating characteristic (ROC) curve (AUC) was used for evaluation.</p><p><strong>Results: </strong>Most factors of the MoCA-B were significantly different between the two groups, and the PSCN group completed the MoCA-B faster (<i>p</i> < 0.05). The AUC analysis showed that for the MoCA-B with a cut-off total score of 23, sensitivity = 85.71%, specificity = 61.22%, Youden's J Index = 0.469, and AUC = 0.832. For the MMSE with a cut-off total score of 25, sensitivity = 70.59%, specificity = 93.75%, Youden's J Index = 0.643, and AUC = 0.885. The AUC of the MMSE was higher than that of the MoCA-B (<i>p</i> > 0.05). The MoCA-B had greater sensitivity and negative predictive value than the MMSE. When considering the cutoffs for identifying mild cognitive impairment (MCI) across different education levels, the MoCA-B had a higher positive rate for PSCI identification (51.2% vs 25%, <i>p</i> < 0.001), indicating that the MoCA-B is suitable for identifying PSCI.</p><p><strong>Conclusion: </strong>The MoCA-B demonstrates higher sensitivity and negative predictive value compared with the MMSE in the screening of post-stroke cognitive impairment patients.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39895"},"PeriodicalIF":1.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional Gene Expression Patterns are Associated with Functional Connectivity Alterations in Major Depressive Disorder with Anxiety Symptoms.","authors":"Chengfeng Chen, Wuyou Bao, Runhua Wang, Wen Qin, Bin Zhang","doi":"10.31083/AP39865","DOIUrl":"https://doi.org/10.31083/AP39865","url":null,"abstract":"<p><strong>Background: </strong>Understanding gene expression and functional connectivity (FC) changes in depressed patients with anxiety can help develop personalized therapies. Herein we examine the link between transcriptome data and FC differences in patients with major depressive disorder with significant anxiety (MDD/ANX+) and patients with major depressive disorder without significant anxiety (MDD/ANX-).</p><p><strong>Methods: </strong>We compared the FC between the MDD/ANX+ group (n = 294) and the MDD/ANX- group (n = 218) to identify FC differences at both edge-based and network levels. Using the Allen Human Brain Atlas, we performed partial least squares regression analysis to identify genes associated with the observed FC disparities, followed by a functional enrichment analysis.</p><p><strong>Results: </strong>The results from both edge-based and network-level FC analyses consistently indicated significantly increased FC between the subcortical network (SC) and visual network, as well as between the SC and dorsal attention network, in the MDD/ANX+ group compared with the MDD/ANX- group. Additionally, transcriptome-neuroimaging correlation analysis revealed that the expression of 1066 genes was spatially correlated with the FC differences between the MDD/ANX+ and MDD/ANX- groups. These genes were enriched in translation at synapses and adenosine triphosphate (ATP) generation.</p><p><strong>Conclusions: </strong>Our results indicate that gene expression variations in synaptic translation and ATP generation may affect FC and anxiety risk in MDD patients.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"26 2","pages":"39865"},"PeriodicalIF":1.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}